



# Financial Tear Sheet

## Corporate Profile

Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at [www.histogenics.com](http://www.histogenics.com).

## Primary IR Contact


Elissa S. Cote  
Vice President, Marketing and External Relations  
Histogenics Corporation  
**Phone:** 781.547.7900  
**E-mail:** [InvestorRelations@histogenics.com](mailto:InvestorRelations@histogenics.com)

## Stock Performance

### HSGX (COMMON STOCK)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Financial Status Indicator</b>	D
<b>Price</b>	\$1.66
<b>Change (%)</b>	▲ 0.01 (0.61%)
<b>Volume</b>	39,758
<b>52 Week Low</b>	\$1.45
<b>Market Cap</b>	\$36,799,029
<b>Rolling EPS</b>	-0.64
<b>PE Ratio</b>	N/A
<b>Shares Outstanding</b>	22,168,090

Data as of 05/26/17 4:00 p.m. ET



## Recent Headlines & Events

05/16/17 - 8:30 a.m.

[Histogenics Corporation to Present at Upcoming Industry Conferences](#)

05/15/17 - 8:32 a.m.

[Histogenics Corporation Receives Innovation Award](#)

05/11/17 - 6:30 a.m.

[Histogenics Corporation Announces First Quarter 2017 Financial and Operating Results](#)

DATE

TITLE

06/01/17

[Histogenics Corp at the Forum for Innovative Regenerative Medicine \(FIRM\) – Regenerative Medicine Crossroad® #4 Conference](#)

**Location** TokyoJP

## SEC Filings

FILING DATE

FORM

05/22/17

CT ORDER

05/19/17

8-K

05/19/17

10-Q/A

05/17/17

4

## Corporate Governance

[Garheng Kong, M.D., Ph.D.](#) Chairman – Founder and Managing Partner of HealthQuest Capital

[Josh Baltzell](#) Managing Director, Split Rock Partners

[David Gill](#) Chairman, Audit Committee

[Adam Gridley](#) President and Chief Executive Officer

[John Johnson](#) Independent Member

[Michael Lewis](#) Chairman of Oceana Investment Partners LLP

[Kevin Rakin](#) Independent Member

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)